Role of the Stress in the Development of the Metabolic Syndrome (STREX)
Recruitment status was: Recruiting
The purpose of this study is determine the incidence of metabolic syndrome (MetS) in people of high risk, of 40 or more years and attended in the Primary Care. Evaluating the association between anxiety, depression, quality of life and the vital stressful events, and the development of the metabolic syndrome in general population.
Our hypothesis is that population of the cohort with bigger degree of stress will develop earlier the metabolic syndrome.
If our hypothesis about the metabolic syndrome are demonstrated, it would allow establishing in a future interventions on these factors of risk to prevent or to decrease the incidence of this syndrome in the Primary Care.
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Role of Anxiety, Depression, Quality of Life and Stressful Vital Events in the Development of the Metabolic Syndrome. StreX Project.|
- Incidence of metabolic syndrome [ Time Frame: One year ]Determining the incidence of metabolic syndrome ( MetS ) in people of high risk, older than 40 years and attended in the Primary Care.
- Association between risk factors and metabolic syndrome [ Time Frame: One year ]Association between anxiety, the depression, the quality of life and the vital stressful events and the metabolic syndrome
|Study Start Date:||December 2008|
|Estimated Study Completion Date:||March 2013|
|Estimated Primary Completion Date:||March 2013 (Final data collection date for primary outcome measure)|
Patients without stress
Patients without any of the next items: Zung's questionnaire score over 19 points; SF-12 questionnaire score over 5 points; Stressful vital events score over 150 points.
Patients with stress
Patients with stress, including: Zung's questionnaire punctuation over 19 points; SF-12 questionnaire score over 5 points; stressful vital events score over 150 points. All combinations are considered positive in stress.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01538082
|Catalan Health Institute. ABS Reus-4|
|Reus, Tarragona, Spain, 43202|
|Principal Investigator:||Yolanda Ortega, MD||Catalan Institute of Health|
|Study Director:||Juan J Cabré, MD, PhD||Catalan Institute of Health|
|Study Chair:||Josep L Piñol, MD, PhD||Catalan Institute of Health|